- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Company Halts Sale of Laproscopic Power Morcellators Used in Fibroid Surgery
Following a FDA advisory earlier in the month of an increased risk of cancer spread, Johnson and Johnson suspended the global sale of a device used in fibroid surgery.
suspended worldwide sale of its device used in fibroid surgery amid concerns over its potential to spread undetected cancer beyond the uterus.
The company said it is suspending the sale of its power morcellators until their role in fibroid treatment is better understood and redefined by the medical community.
The action follows a Food and Drug Administration advisory on April 17 that discouraged doctors from using laparoscopic power morcellators to remove fibroids because of a risk of worsening an often-hidden cancer. (r.reuters.com/dug68v)
"Ethicon morcellation devices have always included cautions in their instructions for use about the potential spread of malignant tissue," J&J wrote in a letter to customers, a copy of which is available with Reuters.
Read the complete story here: http://reut.rs/1rEWZ2Y
Source: Reuters
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
